(b) On February 21, 2013, Michael Zak notified us that he was resigning as a member of our Board of Directors, effective March 31, 2013. Mr. Zak's resignation does not involve any disagreement with us, our management or our Board of Directors.

(d) On February 21, 2013, our Board of Directors appointed Holger Liepmann to serve as a director of the Company with such appointment becoming effective March 31, 2013. Following his appointment becoming effective, Mr. Liepmann will be a director of the class of directors next scheduled for election or re-election, as applicable, by our stockholders at our 2015 annual stockholders' meeting. In addition, following his appointment becoming effective, Mr. Liepmann shall receive the same compensation for his service on our Board of Directors that we provide to our other non-employee directors, namely, an annual retainer of $25,000 and a fee of $1,500 per Board of Director meeting attended, and we also expect Mr. Liepmann at such time to receive a stock option to purchase up to approximately 6,000 shares of our common stock, pursuant to the terms of our 2010 Equity Incentive Plan and consistent with our most recent initial option grants to other new non-employee directors. Additionally, upon his appointment becoming effective, Mr. Liepmann shall enter into our standard form of indemnification agreement in the form attached as Exhibit 10.1 to this Form 8-K and incorporated herein by reference. Mr. Liepmann has not been appointed to serve on any committee of our Board of Directors following his appointment becoming effective.

Mr. Liepmann, 61, most recently served as Executive Vice President of Global Nutrition at Abbott Laboratories, a leading global health care company, until his retirement April 1, 2011. After joining Abbott in 1986 and prior to his appointment as Executive Vice President of Global Nutrition in 2006, Mr. Liepmann held various positions of increasing responsibility at Abbott, including as Executive Vice President, Pharmaceutical Products Group. Before joining Abbott, Mr. Liepmann served as a Marketing Manager, Europe of Cutter Laboratories, a subsidiary of Bayer AG. Mr. Liepmann holds a B.A. in Psychology from Dartmouth College and an M.B.A from Stanford University.

Mr. Zak's contemplated resignation from our Board of Directors, effective March 31, 2013, and the appointment of Mr. Liepmann to our Board of Directors, effective upon the effectiveness of Mr. Zak's resignation, were announced in a press release dated February 26, 2013, which is attached hereto as Exhibit 99.1 and incorporated by reference herein.

(d) Exhibits

10.1    Form of Indemnity Agreement entered into between Verenium Corporation and
        its directors and executive officers, filed as an exhibit to the
        registrant's Current Report on Form 8-K, filed with the Securities and
        Exchange Commission on November 7, 2007, and incorporated herein by
        reference.

99.1    Press Release of Verenium Corporation dated February 26, 2013.